Category: Include on Menu

  • SRX Global Acquires Stake in Vistagen Therapeutics

    SRX Global Acquires Stake in Vistagen Therapeutics

    SRX Global (AMEX:SRXH) disclosed an investment in Vistagen Therapeutics (NASDAQ:VTGN) and said it intends to engage with the company’s leadership and board on potential shareholder value initiatives. Key Investor Takeaways Why SRXH Stock Is in Focus SRX Global (AMEX:SRXH) announced that it has acquired a stake in Vistagen Therapeutics (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company…

  • K Wave Media Signs LOI to Acquire Semiconductor Materials Company as AI Strategy Expands

    K Wave Media Signs LOI to Acquire Semiconductor Materials Company as AI Strategy Expands

    K Wave Media (NASDAQ:KWM) signed an exclusive letter of intent to acquire a controlling stake in a South Korean semiconductor materials company, marking the first proposed acquisition under its long-term AI transformation strategy. Key Investor Takeaways Why KWM Stock Is in Focus K Wave Media (NASDAQ:KWM) announced that it has signed an exclusive letter of…

  • Decent Holding Reports First-Half Fiscal 2026 Revenue Growth as Suncare Business Expands

    Decent Holding Reports First-Half Fiscal 2026 Revenue Growth as Suncare Business Expands

    Decent Holding (NASDAQ:DXST) reported sharply higher first-half revenue driven by wastewater treatment projects and the launch of its AI-powered Suncare senior healthcare platform, while increased expansion costs weighed on earnings. Key Investor Takeaways Why DXST Stock Is in Focus Decent Holding (NASDAQ:DXST) reported unaudited first-half fiscal 2026 revenue of approximately $18.6 million, an increase of…

  • Exagen Reports Record Second-Quarter 2026 Revenue and Raises Full-Year Guidance

    Exagen Reports Record Second-Quarter 2026 Revenue and Raises Full-Year Guidance

    Exagen (NASDAQ:XGN) delivered record quarterly revenue, narrowed losses, improved adjusted EBITDA, and increased its full-year revenue outlook as demand for its autoimmune testing portfolio continued to grow. Key Investor Takeaways Why XGN Stock Is in Focus Exagen (NASDAQ:XGN) reported record second-quarter 2026 revenue of $19.9 million, representing a 16% increase from the same period last…

  • Corvex Signs Multi-Year NVIDIA Blackwell GPU Agreement Without Additional Equity Issuance

    Corvex Signs Multi-Year NVIDIA Blackwell GPU Agreement Without Additional Equity Issuance

    Corvex (NASDAQ:MOVE) secured a multi-year agreement to provide NVIDIA Blackwell GPU infrastructure, funding the expansion through debt, customer prepayments, and existing cash rather than issuing new shares. Key Investor Takeaways Why MOVE Stock Is in Focus Corvex (NASDAQ:MOVE) announced a multi-year agreement to provide clusters of NVIDIA Blackwell GPUs connected through NVIDIA Quantum-2 InfiniBand networking…

  • TNL Mediagene Expands AI Services Through Miro Partnership in Japan

    TNL Mediagene Expands AI Services Through Miro Partnership in Japan

    TNL Mediagene (NASDAQ:TNMG) has partnered with Miro to deliver AI-powered organizational design and human resource development solutions for enterprise customers in Japan, supporting the company’s digital studio growth strategy. Key Investor Takeaways Why TNMG Stock Is in Focus TNL Mediagene (NASDAQ:TNMG) announced that its wholly owned subsidiary, Infobahn, has entered into a strategic partnership with…

  • Autonomix Medical Receives U.S. Patent for Precision Neuromodulation Platform Expansion

    Autonomix Medical Receives U.S. Patent for Precision Neuromodulation Platform Expansion

    Autonomix Medical (NASDAQ:AMIX) expanded its intellectual property portfolio with a new U.S. patent covering technologies for nerve sensing, mapping, and targeted neuromodulation across multiple disease applications. Key Investor Takeaways Why AMIX Stock Is in Focus Autonomix Medical (NASDAQ:AMIX) announced the issuance of U.S. Patent No. 12,433,670, titled “Systems and Methods for Treating Cancer and/or Augmenting…

  • Bruker Reports Second-Quarter 2026 Results as Scientific Instruments Bookings Accelerate

    Bruker Reports Second-Quarter 2026 Results as Scientific Instruments Bookings Accelerate

    Bruker (NASDAQ:BRKR) returned to organic revenue growth in the second quarter, posted stronger bookings across its Scientific Instruments business, and maintained its earnings outlook while adjusting guidance for currency and tax changes. Key Investor Takeaways Why BRKR Stock Is in Focus Bruker (NASDAQ:BRKR) reported second-quarter 2026 revenue of $838.5 million, up 5.2% year over year,…

  • Zebra Technologies Reports Record Second-Quarter 2026 Results and Raises Full-Year Outlook

    Zebra Technologies Reports Record Second-Quarter 2026 Results and Raises Full-Year Outlook

    Zebra Technologies (NASDAQ:ZBRA) posted record second-quarter performance driven by broad-based growth across its business and increased its full-year guidance as demand for automation and AI solutions remained strong. Key Investor Takeaways Why ZBRA Stock Is in Focus Zebra Technologies (NASDAQ:ZBRA) reported record financial results for the second quarter of 2026, highlighting continued demand for its…

  • Westlake Chemical Partners Misses Revenue Expectations in Second Quarter

    Westlake Chemical Partners Misses Revenue Expectations in Second Quarter

    Westlake Chemical Partners LP (NYSE:WLKP) reported second-quarter 2026 results that came in slightly below Wall Street expectations, as revenue missed forecasts and earnings narrowly fell short of analyst estimates. The partnership’s units were little changed in after-hours trading following the announcement. Revenue and Earnings Fall Short of Forecasts Westlake Chemical Partners reported earnings of $0.40…